EnerSpar Corp. (TSE:NRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NurExone Biologic Inc. has embarked on a pre-clinical study to test its exosome-based therapy ExoPTEN for regenerating damaged optic nerves, a breakthrough that could potentially restore vision in cases of glaucoma and other conditions leading to blindness. The market for optic nerve disorder treatments, currently valued at US$3.4 billion, may witness a paradigm shift if NurExone’s innovative treatment, already showing promise in spinal cord injuries, proves to be successful in upcoming trials. This research could redefine the approach to treating optic nerve damage and offer new hope to millions affected by vision loss.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.